Phase 2 N=93 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Number of Participants With Adverse Events (AEs) — 6; 55; 30; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 Vitamin D HIV Study on Postmenopausal Women
HIV
Primary: Change in Bone Mineral Density (BMD) — 0.4; -0.8 percentage change
Phase 2 N=9 Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
Phase 2 N=25 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Phase 2 N=119 Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8 — 26.7; 49.2 Percentage of Participants — p==0.01
Phase 2 N=26 Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) for PI3K GNE-positive Participants Registered to S1400B Treated With GDC-0032. — 1; 13; 5; 1 Participants
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 2 N=62 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
Primary: Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score. — -4.6; -2.7 units on a scale
Phase 2 N=231 Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — -8.0; -7.5; -9.8 Units on a Scale — p=0.746
Phase 2 N=189 Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Actinic Keratosis
Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants
Phase 2 N=64 Study of Tremelimumab in Patients With Advanced Solid Tumors
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Phase 2 N=23 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants
Phase 2 N=50 Theta-Burst Neuromodulation for PTSD
Chronic Post-Traumatic Stress Disorder
Primary: Number of Participants Retained, a Measure of Acceptability of TBS Procedures — 23; 24 Participants
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Phase 2 N=11 Intravenous Immunoglobulin (IVIG) in Lung Transplantation
Hypogammaglobulinemia · Lung Transplantation
Primary: Number of Clinically Diagnosed Bacterial Infections During the Treatment Period — 3; 1 Infections